Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A reAl-World Evidence Study Using Alberta Population Based Data to Describe Treatment Patterns for Metastatic castRation sENsitivE proState Cancer patientS (AWARENESS)

Next Previous
Search
Trial Profile

A reAl-World Evidence Study Using Alberta Population Based Data to Describe Treatment Patterns for Metastatic castRation sENsitivE proState Cancer patientS (AWARENESS)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Leuprorelin (Primary) ; Buserelin; Cyproterone; Degarelix; Goserelin; Histrelin; Leuprorelin; Triptorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms AWARENESS
  • Sponsors Bayer

    • Most Recent Events

    • 08 Feb 2024 Status changed from active, no longer recruiting to completed.
    • 05 Jan 2023 Planned End Date changed from 31 Dec 2022 to 29 Dec 2023.
    • 05 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 29 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top